PKC 412 sensitizes U1810 non-small cell lung cancer cells to DNA damage

Experimental Cell Research

Volumn 305, Issue 1, 2005, Pages 200-213

  Hemström, Therese H ^a   Joseph, Bertrand ^a   Schulte, Gunnar ^a   Lewensohn, Rolf ^b   Zhivotovsky, Boris ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Chemotherapy; Lung cancer; PKC; Radiation

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; CASPASE; CELL PROTEIN; ETOPOSIDE; ISOENZYME; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE B; PROTEIN KINASE C; STAUROSPORINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL COUNT; CELL DEATH; CELL KILLING; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

EID: 15044350672     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.12.017     Document Type: Article

References (54)

1. B. Joseph, P. Marchetti, P. Formstecher, G. Kroemer, R. Lewensohn, and B. Zhivotovsky Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment Oncogene 21 2002 65 77
2. M.D. Parkin, P. Pisani, and J. Ferlay Global cancer statistics C.A. Cancer J. Clin. 49 1999 33 64
3. B. Joseph, R. Lewensohn, and B. Zhivotovsky Role of apoptosis in the response of lung carcinomas to anti-cancer treatment Ann. N. Y. Acad. Sci. 926 2000 204 216
4. R.L. Comis, D.M. Friedland, and B.C. Good Small-cell lung cancer: a perspective on the past and a preview of the future Oncology 12 1998 44 50
5. L. Crinò, and F. Cappuzzo Present and future treatment of advanced non-small cell lung cancer Semin. Oncol. 29 2002 9 16
6. J.C. Reed Apoptosis-targeted therapies for cancer Cancer Cells 3 2003 17 22
7. G. van Loo, X. Saelens, M. van Gurp, M. MacFarlane, S.J. Martin, and P. Vandenabeele The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet Cell Death Differ. 9 2002 1031 1042
8. S.P. Cregan, V.L. Dawson, and R.S. Slack Role of AIF in caspase-dependent and caspase-independent cell death Oncogene 23 2004 2785 2796
9. B. Fadeel, S. Orrenius, and B. Zhivotovsky Apoptosis in human disease: a new skin for the old ceremony? Biochem. Biophys. Res. Commun. 266 1999 699 717
10. R.A. Franklin, and J.A. Mc Cubrey Kinases: positive and negative regulators of apoptosis Leukemia 14 2000 2019 2034
11. J.M. Kurie Role of protein kinase B-dependent signaling in lung tumorigenesis Chest 125 2004 141 144
12. O. David, H. LeBeau, A.R. Brody, M. Friedman, and J. Jett Phospho-AKT overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage Chest 125 2004 152
13. J. Brognard, A.S. Clark, Y. Ni, and P.A. Dennis Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation Cancer Res. 61 2001 3986 3997
14. K. Kandasamy, and R.K. Srivastava Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells Cancer Res. 62 2002 4929 4937
15. L. Ding, H. Wang, W. Lang, and L. Xiao Protein kinase C-e promotes survival of lung cancer cells by No 38 35305-35313 2002.suppressing apoptosis through dysregulation of the mitochondrial caspase pathway J. Biol. Chem. 277 2002 35305 35313
16. A.S. Clark, K.A. West, P.M. Blumberg, and P.A. Dennis Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCd promotes cellular survival and chemotherapeutic resistance Cancer Res. 63 2003 780 786
17. C.A. Carter Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer Curr. Drug Targets 1 2000 163 183
18. S. Vicent, J.M. López-Picazo, G. Toledo, M.D. Lozano, W. Torre, C. Garcia-Corchón, C. Quero, J.-C. Soria, S. Martin-Algarra, R.G. Manzano, and L.M. Montuenga ERK 1/2 is activated in non-small cell lung cancer and associated with advanced tumours Br. J. Cancer 90 2004 1047 1052
19. J. MacKeigan, T. Collins, and J. Ting MEK inhibition enhances paclitaxel-induced tumor apoptosis J. Biol. Chem. 15 2000 38953 38956
20. P. Cohen Protein kinases-the major drug targets of the twenty-first century? Nat. Rev., Drug. Discov. 1 2002 309 315
21. J. Dancey, and E.A. Sausville Issues and progress with protein kinase inhibitors for cancer treatment Nat. Rev., Drug. Discov. 2 2003 296 313
22. B. Joseph, J. Ekedahl, R. Lewensohn, P. Marchetti, P. Formstecher, and B. Zhivotovsky Defective caspase-3 relocalization in non-small cells lung carcinoma Oncogene 20 2001 2877 2888
23. G. Caravatti, T. Meyer, A. Fredenhagen, U. Trinks, H. Mett, and D. Fabbro Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C Bioorg. Med. Chem. Lett. 4 1994 399 404
24. D. Fabbro, E. Buchdunger, J. Wood, J. Mestan, F. Hofmann, S. Ferrari, H. Mett, T. O'Reilly, and T. Meyer Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent Pharmacol. Ther. 82 1999 293 301
25. Y. Ikegami, S. Yano, and K. Nakao Effects of the new selective protein kinase C inhibitor 4′-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells Arzneim.-Forsch./ Drug Res. 46 1996 201 204
26. Y. Ikegami, S. Yano, and K. Nakao Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells Jpn. J. Pharmacol. 70 1996 65 72
27. C. Courage, J. Budworth, and A. Gesher Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation Br. J. Cancer 71 1995 697 704
28. C. Courage, R. Snowden, and A. Gesher Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells Br. J. Cancer 74 1996 1199 1205
29. A. Tenzer, D. Zingg, S. Rocha, B. Hemmings, D. Fabbro, C. Glanzmann, P.A. Scubier, S. Bodis, and M. Pruschy The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C Cancer Res. 61 2001 8203 8210
30. K. Zaugg, S. Rocha, H. Resh, I. Hegyi, C. Oehler, C. Glanzmann, D. Fabbro, S. Bodis, and M. Prusshy Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412 Cancer Res. 61 2001 732 738
31. S. Rosha, M.S. Soengas, S.W. Lowe, C. Glanzmann, D. Fabbro, K. Winterhalter, S. Bodis, and M. Prushy Protein kinase C inhibitor and irradiation-induced apoptosis: relevance of the cytochrome c-mediated caspase-9 pathway Cell Growth Differ. 11 2000 491 499
32. M. Begemann, S.A. Kashimawo, D.F. Heitjan, P.B. Sciff, J.N. Bruce, and B. Weinstein Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity Anticancer Res. 18 1998 2275 2282
33. D. Fabbro, S. Ruetz, S. Bodis, M. Pruschy, K. Csermak, A. Man, P. Campochiaro, J. Wood, T. O'Reilly, and T. Meyer PKC 412-a protein kinase inhibitor with a broad therapeutic potential Anti-Cancer Drug Design 15 2000 17 28
34. Y. Ikegami, S. Yano, K. Nakao, F. Fujita, M. Fujita, Y. Sakamoto, N. Murata, and K. Isowa Antitumor activity of the new selective protein kinase C inhibitor 4′-N-benzoyl staurosporine on murine and human tumor models Arzneim.-Forsch./Drug Res. 45 1995 1225 1230
35. M. Begemann, S.A. Kashimawo, Y.A. Choi, S. Kim, K.M. Christiansen, G. Duigou, M. Mueller, I. Schieren, S. Ghosh, D. Fabbro, N.M. Lampen, D.F. Heitjan, P.B. Schiff, J.N. Bruce, and I.B. Weinstein Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter Clin. Cancer. Res. 2 1996 1017 1030
36. J. Sedlak, L. Hunakova, J. Duraj, B. Chorvath, and L. Novotny Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines Anti-Cancer Drugs 6 1995 70 76
37. K. Ganeshaguru, R.G. Wickremasinghe, D.T. Jones, M. Gordon, S.M. Hart, A.E. Virchis, H.G. Prentice, A.V. Hoffbrand, A. Man, K. Champain, K. Csermak, and A.B. Mehta Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro Haematology 87 2002 167 176
38. Z. Han, P. Pantazis, T.S. Lange, J.H. Wyche, and E.A. Hendrickson The staurosporine analog RO-31-8220, induces apoptosis independently of its ability to inhibit protein kinase C Cell Death Differ. 7 2000 521 530
39. M. Begemann, S.A. Kashimawo, R.M. Lunn, T. Delohery, Y.J.A. Choi, S. Kim, D.F. Heitjan, R.M. Santella, P.B. Sciff, J.N. Bruce, and B. Weinstein Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase Anticancer Res. 18 1998 3139 3152
40. M. Garcia-Calvo, E.P. Peterson, D.M. Rasper, J.P. Vaillancourt, R. Zamboni, D.W. Nicholson, and N.A. Thornberry Purification and catalytic properties of human caspase family members Cell Death Differ. 6 1999 362 369
41. B. Zhivotovsky, D. Wade, A. Gahm, S. Orrenius, and P. Nicotera Formation of 50 kbp chromatin fragments in isolated liver nuclei is mediated by protease and endonuclease activation FEBS Lett. 351 1994 150 154
42. S.T. Harkin, G.M. Cohen, and A. Gescher Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C Mol. Pharmacol. 54 1998 663 670
43. J. Budworth, and A. Gescher Differential inhibition of cytosolic and membrane-derived protein kinase C activity by staurosporine and other kinase inhibitors FEBS Lett. 362 1995 139 142
44. S.E. Wilkinson, P.J. Parker, and J.S. Nixon Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C Biochem. J. 294 1993 335 337
45. K.B. Reddy, S.M. Nabha, and N. Atanaskova Role of MAP kinase in tumor progression and invasion Cancer Metastasis Rev. 22 2003 395 403
46. P. Thavasu, D. Propper, A. McDonald, N. Dobbs, T. Ganesan, D. Talbot, J. Braybrook, F. Caponigro, C. Hutchison, C. Twelves, A. Man, D. Fabbro, A. Harris, and F. Balkwill The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-related kinase 2 expression in cancer patients Cancer Res. 59 1999 3980 3984
47. H.C. Wen, W.C. Huang, A. Ali, J.R. Woodgett, and W.W. Lin Negative regulation of phosphatidylinositol 3-kinase and Akt signalling pathway by PKC Cell Signalling 15 2002 37 45
48. W. Li, J. Zhang, L. Flechner, T. Hyun, A. Yam, T.F. Franke, and J.H. Pierce Protein kinase C-alpha overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal Oncogene 18 1999 6564 6572
49. J. Kabir, M. Lobo, and I. Zachary Staurosporine induces endothelial cell apoptosis via focal adhesion kinase dephosphorylation and focal adhesion disassembly independent of focal adhesion kinase proteolysis Biochem. J. 367 2002 145 155
50. M.-A. Gallego, B. Joseph, T.H. Hemström, S. Tamiji, L. Mortier, G. Kroemer, P. Formstecher, B. Zhivotovsky, and P. Marchetti Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas Oncogene 23 2004 6282 6291
51. E. Daugas, D. Nochy, L. Ravagnan, M. Loeffler, S.A. Susin, N. Zamzami, and G. Kroemer Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis FEBS Lett. 476 2000 118 123
52. P.C. Mack, D.R. Gandara, A.H. Lau, P.N. Lara Jr., M.J. Edelman, and P.H. Gumerlock Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma Cancer Chemother. Pharmacol. 51 2003 337 348
53. S.H. Kaufmann Cell death induced by topoisomerase-targeted drugs: more questions than answers Biochim. Biophys. Acta 1400 1998 195 211
54. C. Monnerat, R. Henriksson, T. Le Chevalier, S. Novello, P. Berthaud, S. Faivre, and E. Raymond Phase I study of PKC 412 (N-benzoyl-staurosporine), a novel oral protein kinase inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer Ann. Oncol. 15 2004 316 323